2 results
Not approvedWill not start
The primary objective of this study is to demonstrate that the IOP-lowering efficacy of Travoprost Ophthalmic Solution, 0.004% (preserved with POLYQUAD) is noninferior to Timolol Ophthalmic Solution (0.5% or 0.25%) in pediatric glaucoma patients.
Approved WMOPending
To further evaluate the safety, efficacy and device performance of the ACURATE neo2* aortic bioprosthesis and ACURATE neo2* transfemoral delivery system in 2000 consecutive patients with severe aortic stenosis according to VARC-3 criteria.